CoChat

Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials

de Mesquita, Yasmin Luz Lima, Pera Calvi, Izabela, Reis Marques, Isabela, Almeida Cruz, Sara, Padrao, Eduardo Messias Hirano, Carvalho, Pedro Emanuel de Paula, da Silva, Caroliny Hellen Azevedo, Cardoso, Rhanderson, Moura, Filipe Azevedo, Rafalskiy, Vladimir Vitalievich · 2023 · International Journal of Obesity

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Abstract

Objectives Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes. We performed a meta-analysis to assess tirzepatide's weight reduction efficacy and safety.Methods We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight. Mean difference (MD) and odds ratio (OR) were calculated for continuous and binary outcomes, respectively. Review Manager 5.4.1 and RStudio were used for the statistical analysis, and RoB-2 (Cochrane) to assess the risk of bias.Results Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included. Pooled analysis showed that tirzepatide 5 mg, 10 mg, and 15 mg were more effective than placebo, with MD in body weight of -7.7 kg (95% CI -11.0, -4.4; p < 0.001), -11.6 kg (95% CI -18.8, -4.3; p = 0.002), and -11.8 kg (95% CI -17.4, -6.2; p < 0.001), respectively, and MD in percent change in weight of -8.1% (95% CI -11.0, -5.2; p < 0.001), -11.9% (95% CI -18.1, -5.6; p < 0.001), and -12.4% (95% CI -17.2, -7.5; p < 0.001), respectively. Tirzepatide also reduced BMI and waist circumference. Adverse events were more common with tirzepatide with respect to nausea (OR 4.2; 95% CI 2.4, 7.5; p < 0.001), vomiting (OR 7.0; 95% CI 4.3, 11.4; p < 0.001), and diarrhea (OR 2.8; 95% CI 1.6, 4.9; p < 0.001) (15 mg dose), when compared with placebo.Conclusions The results support that tirzepatide leads to substantial weight reduction and constitutes a valuable therapeutic option for weight management, despite an increase in gastrointestinal symptoms.Protocol registration CRD42022348576.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41366-023-01337-x

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 1

  1. The Cochrane Collaboration. Review Manager (RevMan): Version 5.4.1. 2020. https://training.cochrane.org/online-learning/core-software/revman.

Cited by

See all 59

Metadata

Authors
de Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V.
Affiliations
  • Brigham and Women's Hospital (US)
  • Immanuel Kant Baltic Federal University (RU)
Venue
International Journal of Obesity
Published
2023-07-17
Volume
47
Issue
10
Pages
883-892
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W4384521950
Cited by
59
References
38
Citations by year
2026: 12 · 2025: 21 · 2024: 22 · 2023: 4
FWCI
2.14
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • International Journal of Obesity (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (T32HL007604)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
tirzepatide, GIP/GLP-1 receptor agonist, weight loss, obesity, type 2 diabetes, body mass index, waist circumference, nausea, vomiting, diarrhea, adverse events, drug safety, dose-response relationship, placebo comparison, risk of bias, serious adverse events
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Weight Loss, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1038/s41366-023-01337-x
The paper
de Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V. (2023). Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. International Journal of Obesity. https://doi.org/10.1038/s41366-023-01337-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.